Toronto Centre for Liver Disease, Sandra Rotman Centre for Global Health, University of Toronto, Toronto, Canada.
Queen Mary University London, London, UK.
J Hepatol. 2016 Oct;65(1 Suppl):S130-S142. doi: 10.1016/j.jhep.2016.07.007.
The rapid progress in the development of direct-acting antiviral agents for hepatitis C has allowed the vast majority of patients to receive all oral therapy that will eliminate their virus. The success of the new regimens has led many to question the need for further developments in this field. Major improvements in drugs for hepatitis C are unlikely but we predict incremental improvements in the next few years. We hope that the next generation of drugs will address the unresolved issues for patients with genotype 3 infection where current treatments are still not entirely satisfactory and we anticipate improvements in the management of patients with renal failure. Shorter duration treatments, perhaps with novel modes of action, may allow simplified 'one-dose' treatments that will greatly expand our ability to treat patients who have difficulty accessing current services and we anticipate that the clinical community will better define the patients with advanced disease who will benefit from therapy prior to liver transplantation.
直接作用抗病毒药物在丙型肝炎治疗方面的快速发展使得绝大多数患者都能接受全口服治疗，从而清除病毒。新方案的成功应用使许多人开始质疑该领域是否还需要进一步的发展。虽然用于丙型肝炎的药物不太可能有重大改进，但我们预计在未来几年内会有一些渐进的改善。我们希望下一代药物能够解决基因型 3 感染患者的未解决问题，因为目前的治疗方法仍然不完全令人满意，我们还预计在肾衰竭患者的治疗管理方面会有所改善。较短疗程的治疗方法，也许具有新颖的作用机制，可能会使简化的“一剂治疗”成为可能，这将极大地提高我们治疗难以获得现有服务的患者的能力，我们预计临床界将更好地确定在肝移植前受益于治疗的晚期疾病患者。
